Sign In
Buy CTMX
$3.16
-0.290 (-8.41%)
At Close: Jun 02, 2026
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
10:46pm, Tuesday, 17'th Mar 2026
SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
11:41am, Tuesday, 17'th Mar 2026
CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastatic CRC show rising response rates and strong disease control.
Boothbay Fund Management LLC Buys Shares of 1,237,057 CytomX Therapeutics, Inc. $CTMX
04:02am, Tuesday, 17'th Mar 2026
Boothbay Fund Management LLC purchased a new position in CytomX Therapeutics, Inc. (NASDAQ: CTMX) during the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
06:36pm, Monday, 16'th Mar 2026
CytomX Therapeutics (CTMX +44.44%), a biotech company that develops conditionally activated biologics for cancer treatment, closed Monday at $6.75, up 44.23%. The stock is jumping after releasing Phas
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:04pm, Monday, 16'th Mar 2026
SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has
CytomX: The Probody Mask Just Slipped, And Investors Like What They See (Upgrade)
01:59pm, Monday, 16'th Mar 2026
CytomX Therapeutics, Inc. receives a speculative Buy upgrade following promising new mCRC data for lead asset Varseta-M (CX-2051). Varseta-M shows a clear dose response and manageable safety profile w
Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally
12:38pm, Monday, 16'th Mar 2026
The latest data revealed on Monday confirmed response rates in expansion cohorts of 32% at a 10 mg/kg Q3W dose and 20% at an 8.6 mg/kg Q3W dose, with an estimated progression-free survival of 7.1 mont
CytomX Therapeutics, Inc. (CTMX) Q4 2025 Earnings Call Transcript
12:03pm, Monday, 16'th Mar 2026
CytomX Therapeutics, Inc. (CTMX) Q4 2025 Earnings Call Transcript
CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates
09:26am, Monday, 16'th Mar 2026
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.22 per share a year ago.
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
07:05am, Monday, 16'th Mar 2026
- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) -
- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - -
CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
01:25am, Monday, 16'th Mar 2026
CytomX Therapeutics, Inc. (NASDAQ: CTMX) will release its fourth-quarter earnings before the opening bell on Monday, March 16.
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of “Moderate Buy” from Brokerages
04:26am, Wednesday, 11'th Mar 2026
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight brokerages that are covering the stock, Marketbeat Ratings reports. One equi
CytomX Therapeutics Target of Unusually Large Options Trading (NASDAQ:CTMX)
01:14am, Thursday, 05'th Mar 2026
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders bought 20,170 call options on the company. This is
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
08:00am, Wednesday, 04'th Mar 2026
SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it wi
